One-Shot gene therapy could replace monthly eye injections for wet AMD
NCT ID NCT06550011
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for frequent anti-VEGF injections by helping the eye produce its own medicine. About 18 adults aged 50 to 89 with wet AMD will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AMD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bay Area Retina Associates
Walnut Creek, California, 94598, United States
-
California Retina Consultants
Bakersfield, California, 93309, United States
-
Retina Consultants of Texas
The Woodlands, Texas, 77384, United States
-
Retina Consultants of Texas - San Antonio
San Antonio, Texas, 78240, United States